<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523414004735</prism:url><dc:identifier>doi:10.1016/j.ejmech.2014.05.049</dc:identifier><eid>1-s2.0-S0223523414004735</eid><prism:doi>10.1016/j.ejmech.2014.05.049</prism:doi><pii>S0223-5234(14)00473-5</pii><dc:title>Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3) </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>82</prism:volume><prism:startingPage>195</prism:startingpage><prism:endingPage>203</prism:endingpage><prism:pageRange>195-203</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2014-07-23</prism:coverdate><prism:coverDisplayDate>23 July 2014</prism:coverdisplaydate><prism:copyright>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Chen, Haijun</dc:creator><dc:creator>Yang, Zhengduo</dc:creator><dc:creator>Ding, Chunyong</dc:creator><dc:creator>Xiong, Ailian</dc:creator><dc:creator>Wild, Christopher</dc:creator><dc:creator>Wang, Lili</dc:creator><dc:creator>Ye, Na</dc:creator><dc:creator>Cai, Guoshuai</dc:creator><dc:creator>Flores, Rudolfo M.</dc:creator><dc:creator>Ding, Ye</dc:creator><dc:creator>Shen, Qiang</dc:creator><dc:creator>Zhou, Jia</dc:creator><dc:description>
                  In a continuing effort to develop orally bioavailable small-molecule STAT3 inhibitors as potential therapeutic agents for human cancer, a series of novel diversified analogues based on our identified lead compound HJC0149 (1) (5-chloro-N-(1,1-dioxo-1H-1λ6-benzo[b]thiophen-6-yl)-2-hydroxybenzamide, Eur. J. Med. Chem. 2013, 62, 498–507) have been rationally designed, synthesized, and pharmacologically evaluated. Molecular docking studies and biological characterization supported our earlier findings that the O-alkylamino-tethered side chain on the hydroxyl group is an effective and essential structural determinant for improving biological activities and druglike properties of these molecules. Compounds with such modifications exhibited potent antiproliferative effects against breast and pancreatic cancer cell lines with IC50 values from low micromolar to nanomolar range. Among them, the newly discovered STAT3 inhibitor 12 (HJC0416) displayed an intriguing anticancer profile both in vitro and in vivo (i.p. & p.o.). More importantly, HJC0416 is an orally bioavailable anticancer agent as a promising candidate for further development.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>STAT3 inhibitors</dcterms:subject><dcterms:subject>Oral bioavailability</dcterms:subject><dcterms:subject>Breast cancer</dcterms:subject><dcterms:subject>Pancreatic cancer</dcterms:subject><dcterms:subject>Anticancer agents</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523414004735" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523414004735" rel="scidir"/></link></coredata><objects><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="100" height="30" size="5966">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="69" height="50" size="6964">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="91" height="49" size="6527">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="76" height="51" size="6743">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="97" height="50" size="6719">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="260" size="17913">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="78" height="39" size="6074">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="573" size="92482">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="200" size="43552">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="493" height="118" size="15265">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="106" size="13591">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="511" height="215" size="34450">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="79" height="30" size="5884">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="86" height="48" size="6117">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="106" height="50" size="6608">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="273" size="36964">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="400" size="52936">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="301" size="44451">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="350" size="43260">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="109" height="50" size="6501">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="71" height="30" size="5868">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="64" height="30" size="5741">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="67" size="2388">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="157" size="3446">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="118" size="2632">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="148" size="3047">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="2685">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="147" size="4943">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="110" size="2729">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="110" height="163" size="13788">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="9722">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2277">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2455">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="5199">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="82" size="2687">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="2613">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="103" size="2686">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="103" size="3425">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="152" size="4886">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="124" size="5117">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="181" height="164" size="6546">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="2464">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="2705">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="103" size="2701">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="4824428">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414004735-mmc1.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>84902175603</scopus-id><scopus-eid>2-s2.0-84902175603</scopus-eid><pubmed-id>24904966</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/84902175603" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20140522">2014-05-22</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20140522">2014-05-22</xocs:available-online-date>
      <xocs:ew-transaction-id>2014-06-25T01:17:50</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523414004735</xocs:eid>
      <xocs:pii-formatted>S0223-5234(14)00473-5</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523414004735</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2014.05.049</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523414X00103</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20150514">2015-05-14T05:55:44.535656-04:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20140723</xocs:date-search-begin>
      <xocs:year-nav>2014</xocs:year-nav>
      <xocs:indexeddate epoch="1400716800">2014-05-22T00:00:00Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes highlightsabst primabst pubtype ref specialabst alllist content subj ssids</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>82</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>82</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 82</xocs:vol-iss-suppl-text>
      <xocs:sort-order>17</xocs:sort-order>
      <xocs:first-fp>195</xocs:first-fp>
      <xocs:last-lp>203</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>195</xocs:first-page>
         <xocs:last-page>203</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20140723</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>23 July 2014</xocs:cover-date-text>
      <xocs:cover-date-start>2014-07-23</xocs:cover-date-start>
      <xocs:cover-date-year>2014</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DISCOVERYPOTENTANTICANCERAGENTHJC0416ORALLYBIOAVAILABLESMALLMOLECULEINHIBITORSIGNALTRANSDUCERACTIVATORTRANSCRIPTION3STAT3</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>CHEN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>H</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(2-Bromoethoxy)-5-chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)benzamide (<ce:bold>2</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-fluoroethoxy)benzamide (<ce:bold>3</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(1-methylpiperidin-4-yloxy) benzamide (<ce:bold>4</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-2-(2-dimethylamino-ethoxy)-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl) benzamide (<ce:bold>5</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-morpholin-4-yl-ethoxy) benzamide (<ce:bold>6</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-piperidin-1-yl-ethoxy)benzamide (<ce:bold>7</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-[2-(4-methylpiperazin-1-yl)-ethoxy]benzamide (<ce:bold>8</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-piperazin-1-yl-ethoxy) benzamide (<ce:bold>9</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(piperidin-4-yloxy)benzamide (<ce:bold>10</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(2-Aminoethoxy)-5-chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)benzamide (<ce:bold>11</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(3-Aminopropoxy)-5-chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)benzamide (<ce:bold>12</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-methylaminoethoxy)benzamide (<ce:bold>13</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.13</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-N-(3-methoxy-1,1-dioxo-2,3-dihydro-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-hydroxybenzamide (<ce:bold>14</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vitro</ce:italic> determination of effects of synthesized compounds on cancer cell proliferation</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Transient transfection and dual luciferase reporter assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Molecular docking studies</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vivo</ce:italic> antitumor activity assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Conflict of interest</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>1630</xocs:ref-first-fp>
            <xocs:ref-last-lp>1635</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>BOWMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2474</xocs:ref-first-fp>
            <xocs:ref-last-lp>2488</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2468</xocs:ref-first-fp>
            <xocs:ref-last-lp>2473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>6613</xocs:ref-first-fp>
            <xocs:ref-last-lp>6626</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1139</xocs:ref-first-fp>
            <xocs:ref-last-lp>1142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>YUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>45</xocs:ref-first-fp>
            <xocs:ref-last-lp>56</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>HAFTCHENARY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>115</xocs:ref-first-fp>
            <xocs:ref-last-lp>127</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>BUETTNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>945</xocs:ref-first-fp>
            <xocs:ref-last-lp>954</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>295</xocs:ref-first-fp>
            <xocs:ref-last-lp>303</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>595</xocs:ref-first-fp>
            <xocs:ref-last-lp>596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>DENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>91</xocs:ref-first-fp>
            <xocs:ref-last-lp>107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>ALZAIDSIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>254</xocs:ref-first-fp>
            <xocs:ref-last-lp>267</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>HANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>355</xocs:ref-first-fp>
            <xocs:ref-last-lp>365</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>507</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>180</xocs:ref-first-fp>
            <xocs:ref-last-lp>185</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>INNOCENTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4872</xocs:ref-first-fp>
            <xocs:ref-last-lp>4876</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>TANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3429</xocs:ref-first-fp>
            <xocs:ref-last-lp>3433</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>TROTT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>455</xocs:ref-first-fp>
            <xocs:ref-last-lp>461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>SHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>366</xocs:ref-first-fp>
            <xocs:ref-last-lp>377</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>BECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>145</xocs:ref-first-fp>
            <xocs:ref-last-lp>151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>4038</xocs:ref-first-fp>
            <xocs:ref-last-lp>4043</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>226</xocs:ref-first-fp>
            <xocs:ref-last-lp>230</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>CHENX2014X195</xocs:refkey3>
         <xocs:refkey4lp>CHENX2014X195X203</xocs:refkey4lp>
         <xocs:refkey4ai>CHENX2014X195XH</xocs:refkey4ai>
         <xocs:refkey5>CHENX2014X195X203XH</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(14)00473-5</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523414004735</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523414004735</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2014.05.049</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2014-06-25T02:50:47.093494-04:00</xocs:timestamp>
         <xocs:cover-date-start>2014-07-23</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/MAIN/application/pdf/b84c6d756e649de8b470d669829009e7/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/MAIN/application/pdf/b84c6d756e649de8b470d669829009e7/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1718991</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>9</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523414004735-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/PREVIEW/image/png/cc7ac207b610e5fddf49c35a922deef0/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/PREVIEW/image/png/cc7ac207b610e5fddf49c35a922deef0/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>58457</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx13/DOWNSAMPLED/image/jpeg/0d20aba90f8899f3144273dfa40015b4/fx13.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx13/DOWNSAMPLED/image/jpeg/0d20aba90f8899f3144273dfa40015b4/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5966</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>100</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx11/DOWNSAMPLED/image/jpeg/9421290f5f47a1ce7ee87931bf8e8958/fx11.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx11/DOWNSAMPLED/image/jpeg/9421290f5f47a1ce7ee87931bf8e8958/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6964</xocs:filesize>
               <xocs:pixel-height>50</xocs:pixel-height>
               <xocs:pixel-width>69</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx8/DOWNSAMPLED/image/jpeg/6b0864cd4d4149518ec25f7e146446ed/fx8.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx8/DOWNSAMPLED/image/jpeg/6b0864cd4d4149518ec25f7e146446ed/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6527</xocs:filesize>
               <xocs:pixel-height>49</xocs:pixel-height>
               <xocs:pixel-width>91</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx5/DOWNSAMPLED/image/jpeg/ee5c60da9f62128686c6f3750d7bb317/fx5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx5/DOWNSAMPLED/image/jpeg/ee5c60da9f62128686c6f3750d7bb317/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6743</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>76</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx7/DOWNSAMPLED/image/jpeg/2e641d0d7186cb7efcc314b608bff5ef/fx7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx7/DOWNSAMPLED/image/jpeg/2e641d0d7186cb7efcc314b608bff5ef/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6719</xocs:filesize>
               <xocs:pixel-height>50</xocs:pixel-height>
               <xocs:pixel-width>97</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr3/DOWNSAMPLED/image/jpeg/b561191272c14f850df71f24dc3b6cbf/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr3/DOWNSAMPLED/image/jpeg/b561191272c14f850df71f24dc3b6cbf/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17913</xocs:filesize>
               <xocs:pixel-height>260</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx14/DOWNSAMPLED/image/jpeg/9ea5a4f603d0ac7f44ffa723136d8c3b/fx14.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx14/DOWNSAMPLED/image/jpeg/9ea5a4f603d0ac7f44ffa723136d8c3b/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6074</xocs:filesize>
               <xocs:pixel-height>39</xocs:pixel-height>
               <xocs:pixel-width>78</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr4/DOWNSAMPLED/image/jpeg/62a49cb7a8afd5a0d7bb55599e3426b6/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr4/DOWNSAMPLED/image/jpeg/62a49cb7a8afd5a0d7bb55599e3426b6/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>92482</xocs:filesize>
               <xocs:pixel-height>573</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx1/DOWNSAMPLED/image/jpeg/16aafa70c76a44cde343128a6850a137/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx1/DOWNSAMPLED/image/jpeg/16aafa70c76a44cde343128a6850a137/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43552</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx2/DOWNSAMPLED/image/jpeg/85b518c79a0ddeeb5c1b902cfb3b6499/fx2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx2/DOWNSAMPLED/image/jpeg/85b518c79a0ddeeb5c1b902cfb3b6499/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>15265</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>493</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/sc2/DOWNSAMPLED/image/jpeg/a86f7dd22e4b146b63a786a8a3214f71/sc2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/sc2/DOWNSAMPLED/image/jpeg/a86f7dd22e4b146b63a786a8a3214f71/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>13591</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr2/DOWNSAMPLED/image/jpeg/6a2c8c3eaf4dad1f15a4232d44876fb3/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr2/DOWNSAMPLED/image/jpeg/6a2c8c3eaf4dad1f15a4232d44876fb3/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34450</xocs:filesize>
               <xocs:pixel-height>215</xocs:pixel-height>
               <xocs:pixel-width>511</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx12/DOWNSAMPLED/image/jpeg/1a708d2f1cdaf77c6edcb9b4e8c8475e/fx12.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx12/DOWNSAMPLED/image/jpeg/1a708d2f1cdaf77c6edcb9b4e8c8475e/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5884</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>79</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx6/DOWNSAMPLED/image/jpeg/fd73964daefa2e9948af45abf7d31656/fx6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx6/DOWNSAMPLED/image/jpeg/fd73964daefa2e9948af45abf7d31656/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6117</xocs:filesize>
               <xocs:pixel-height>48</xocs:pixel-height>
               <xocs:pixel-width>86</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx10/DOWNSAMPLED/image/jpeg/3eb48bc6b52c0f73ba0d2c3e451f9c8c/fx10.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx10/DOWNSAMPLED/image/jpeg/3eb48bc6b52c0f73ba0d2c3e451f9c8c/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6608</xocs:filesize>
               <xocs:pixel-height>50</xocs:pixel-height>
               <xocs:pixel-width>106</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr6/DOWNSAMPLED/image/jpeg/9e5f2d93f9a52540d6cbaab5a6a33dd8/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr6/DOWNSAMPLED/image/jpeg/9e5f2d93f9a52540d6cbaab5a6a33dd8/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36964</xocs:filesize>
               <xocs:pixel-height>273</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/sc1/DOWNSAMPLED/image/jpeg/f3e2f0bed5275ab00baecac1a1dd25df/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/sc1/DOWNSAMPLED/image/jpeg/f3e2f0bed5275ab00baecac1a1dd25df/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>52936</xocs:filesize>
               <xocs:pixel-height>400</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr1/DOWNSAMPLED/image/jpeg/20aa57493d4fd00733514e53146c1aab/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr1/DOWNSAMPLED/image/jpeg/20aa57493d4fd00733514e53146c1aab/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>44451</xocs:filesize>
               <xocs:pixel-height>301</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr5/DOWNSAMPLED/image/jpeg/3791ef36797f5cde1506b77aa5c7b34e/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr5/DOWNSAMPLED/image/jpeg/3791ef36797f5cde1506b77aa5c7b34e/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43260</xocs:filesize>
               <xocs:pixel-height>350</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx9/DOWNSAMPLED/image/jpeg/4339aa5795fdaca1f05ba39491135232/fx9.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx9/DOWNSAMPLED/image/jpeg/4339aa5795fdaca1f05ba39491135232/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6501</xocs:filesize>
               <xocs:pixel-height>50</xocs:pixel-height>
               <xocs:pixel-width>109</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx3/DOWNSAMPLED/image/jpeg/3423a831c01f93515d3bcdc27c7582fb/fx3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx3/DOWNSAMPLED/image/jpeg/3423a831c01f93515d3bcdc27c7582fb/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5868</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>71</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx4/DOWNSAMPLED/image/jpeg/2642fe3130154758573ce9a026293c34/fx4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx4/DOWNSAMPLED/image/jpeg/2642fe3130154758573ce9a026293c34/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5741</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>64</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx13/THUMBNAIL/image/gif/55f7f385fc4adef2d07d0e266330c304/fx13.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx13/THUMBNAIL/image/gif/55f7f385fc4adef2d07d0e266330c304/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2388</xocs:filesize>
               <xocs:pixel-height>67</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx11/THUMBNAIL/image/gif/3b41bb3d2871a88a06163bac1c5ebfa4/fx11.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx11/THUMBNAIL/image/gif/3b41bb3d2871a88a06163bac1c5ebfa4/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3446</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx8/THUMBNAIL/image/gif/7f8cd0f8ab2594725bca590ebc6adf47/fx8.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx8/THUMBNAIL/image/gif/7f8cd0f8ab2594725bca590ebc6adf47/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2632</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx5/THUMBNAIL/image/gif/1d73c6b2bbf73e1cb7578413c4128368/fx5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx5/THUMBNAIL/image/gif/1d73c6b2bbf73e1cb7578413c4128368/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3047</xocs:filesize>
               <xocs:pixel-height>148</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx7/THUMBNAIL/image/gif/ed4b54ab63cd4d6c60c3bfbcdba14591/fx7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx7/THUMBNAIL/image/gif/ed4b54ab63cd4d6c60c3bfbcdba14591/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2685</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr3/THUMBNAIL/image/gif/8cfaf5f2de6ef676716ff29db249291c/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr3/THUMBNAIL/image/gif/8cfaf5f2de6ef676716ff29db249291c/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4943</xocs:filesize>
               <xocs:pixel-height>147</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx14/THUMBNAIL/image/gif/787834063608261f6553b2cc47ead6d0/fx14.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx14/THUMBNAIL/image/gif/787834063608261f6553b2cc47ead6d0/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2729</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr4/THUMBNAIL/image/gif/af36007ed369db71932c7ac1a551d5bf/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr4/THUMBNAIL/image/gif/af36007ed369db71932c7ac1a551d5bf/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13788</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>110</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx1/THUMBNAIL/image/gif/565ed7bd4e46fc07e25baa706e5736c7/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx1/THUMBNAIL/image/gif/565ed7bd4e46fc07e25baa706e5736c7/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9722</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx2/THUMBNAIL/image/gif/0428cdb60c3fed532b01e5b44ba3b83c/fx2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx2/THUMBNAIL/image/gif/0428cdb60c3fed532b01e5b44ba3b83c/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2277</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/sc2/THUMBNAIL/image/gif/5f556950095972cdaa4e9f388bdffd95/sc2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/sc2/THUMBNAIL/image/gif/5f556950095972cdaa4e9f388bdffd95/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2455</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr2/THUMBNAIL/image/gif/4d3f7c49ab2a531071674cd577a96c39/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr2/THUMBNAIL/image/gif/4d3f7c49ab2a531071674cd577a96c39/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5199</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx12/THUMBNAIL/image/gif/d0372c9beeee3603bc9d476f9a24a4ae/fx12.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx12/THUMBNAIL/image/gif/d0372c9beeee3603bc9d476f9a24a4ae/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2687</xocs:filesize>
               <xocs:pixel-height>82</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx6/THUMBNAIL/image/gif/3b3d4955e11e472aafab8cd4ad08e7cc/fx6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx6/THUMBNAIL/image/gif/3b3d4955e11e472aafab8cd4ad08e7cc/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2613</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx10/THUMBNAIL/image/gif/3f987fc5cb0f6727e273e8d7b58668c8/fx10.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx10/THUMBNAIL/image/gif/3f987fc5cb0f6727e273e8d7b58668c8/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2686</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr6/THUMBNAIL/image/gif/e46e83f1e067babf32b805fd1b972ddb/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr6/THUMBNAIL/image/gif/e46e83f1e067babf32b805fd1b972ddb/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3425</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/sc1/THUMBNAIL/image/gif/531acea0add2215d97c2d76eb6098069/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/sc1/THUMBNAIL/image/gif/531acea0add2215d97c2d76eb6098069/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4886</xocs:filesize>
               <xocs:pixel-height>152</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr1/THUMBNAIL/image/gif/1e18fc83ae95eb04af41a8e26f97ba8d/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr1/THUMBNAIL/image/gif/1e18fc83ae95eb04af41a8e26f97ba8d/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5117</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/gr5/THUMBNAIL/image/gif/2cae7d7815afe949a13203284021d3d2/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/gr5/THUMBNAIL/image/gif/2cae7d7815afe949a13203284021d3d2/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6546</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx9/THUMBNAIL/image/gif/f8bb80787b7a5658fac0585916c07aa4/fx9.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx9/THUMBNAIL/image/gif/f8bb80787b7a5658fac0585916c07aa4/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2464</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx3/THUMBNAIL/image/gif/422c55a7ecb1d8d3313a1e41a8e1b9d6/fx3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx3/THUMBNAIL/image/gif/422c55a7ecb1d8d3313a1e41a8e1b9d6/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2705</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/fx4/THUMBNAIL/image/gif/15b540280228002e2f2d4de8dd3414c1/fx4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/fx4/THUMBNAIL/image/gif/15b540280228002e2f2d4de8dd3414c1/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2701</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414004735-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414004735/mmc1/MAIN/application/pdf/18f04a237b8879fdaa4cf9df68348f9e/mmc1.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414004735/mmc1/MAIN/application/pdf/18f04a237b8879fdaa4cf9df68348f9e/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>4824428</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.2" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>7007</aid>
            <ce:pii>S0223-5234(14)00473-5</ce:pii>
            <ce:doi>10.1016/j.ejmech.2014.05.049</ce:doi>
            <ce:copyright type="full-transfer" year="2014">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0010" view="all">Previous work and drug design strategy for the current work.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0015" view="all">Effects of <ce:bold>12</ce:bold> (<ce:bold>HJC0416</ce:bold>) and stattic on cell growth and cellular morphological changes. Exponentially growing MDA-MB-231 breast cancer cells were incubated with <ce:bold>12</ce:bold> or stattic for 48 h. Cell morphology was evaluated under light microscopy.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0020" view="all">Compound <ce:bold>12</ce:bold> (<ce:bold>HJC0416</ce:bold>) inhibited the STAT3 mediated luciferase reporter activity in MDA-MB-231 cells. STAT3 promoter activity was measured using dual luciferase assay with a STAT3 reporter. Promoter activity obtained from DMSO-treated MDA-MB-231 cells was used as control. Error bars represent standard deviation of triplicate wells. Representative experiment from at least 3 independent experiments is shown. RLU: relative luciferase unit.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0025" view="all">Predicted binding modes for <ce:bold>HJC0149</ce:bold> (<ce:bold>1</ce:bold>) and <ce:bold>HJC0416</ce:bold> (<ce:bold>12</ce:bold>). The figures were generated using Pymol.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0030" view="all">Western blot analysis of biochemical markers for apoptosis induction and inhibition of STAT3 activity by stattic and compound <ce:bold>12</ce:bold> in the MDA-MB-231 cell line. Cells were treated with stattic or <ce:bold>12</ce:bold> for 12 h, levels of pSTAT3, STAT3, cleaved caspase-3, PARP-1, cleaved PARP-1 and cyclin D1 were probed by specific antibodies. β-actin was used as the loading control.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0035" view="all">
                     <ce:italic>In vivo</ce:italic> efficacy of compound <ce:bold>12</ce:bold> (<ce:bold>HJC0416</ce:bold>) in inhibiting growth of xenograft tumors (triple-negative breast cancer MDA-MB-231) in mice via A) i.p. or B) oral gavage (p.o.) routes.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:link locator="sc1"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:link locator="sc2"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="tspara0010" view="all">Effects of newly synthesized analogues <ce:bold>2</ce:bold>–<ce:bold>14</ce:bold> on proliferation of human breast and pancreatic cancer cell lines.</ce:simple-para>
               </ce:caption>
               <ce:link locator="fx2"/></ce:link>
               <tgroup cols="8">
                  <colspec colnum="1" colname="col1" colwidth="11*"/></colspec>
                  <colspec colnum="2" colname="col2" colwidth="18*"/></colspec>
                  <colspec colnum="3" colname="col3" colwidth="9*"/></colspec>
                  <colspec colnum="4" colname="col4" colwidth="7*"/></colspec>
                  <colspec colnum="5" colname="col5" colwidth="19*"/></colspec>
                  <colspec colnum="6" colname="col6" colwidth="19*"/></colspec>
                  <colspec colnum="7" colname="col7" colwidth="8*"/></colspec>
                  <colspec colnum="8" colname="col8" colwidth="3*"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">cLog <italic>P</italic>
                           <cross-ref refid="tbl1fna" id="crosref0210">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">tPSA<cross-ref refid="tbl1fnb" id="crosref0215">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col5" nameend="col8">IC<inf loc="post">50</inf> (μM)<cross-ref refid="tbl1fnc" id="crosref0220">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Breast cancer ER-positive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Breast cancer ER-negative</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col7" nameend="col8">Pancreatic cancer</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AsPC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Panc-1</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>Stattic</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">80.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.89</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.77</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.88</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">83.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">0.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx3"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">72.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">>10<cross-ref refid="tbl1fnd" id="crosref0225">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ND<cross-ref refid="tbl1fne" id="crosref0230">
                              <sup loc="post">e</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx4"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">72.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">4.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">4.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">9.53</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx5"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">75.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.68</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.36</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx6"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">75.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.38</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx7"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">84.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">0.49</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">5.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">6.95</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx8"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">75.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.81</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx9"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">79.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">4.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx10"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">87.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.56</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.69</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx11"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">84.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">4.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">4.09</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx12"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">98.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.25</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx13"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">98.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.97</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">1.88</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx14"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">84.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3.09</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">2.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">92.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">6.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">7.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">8.39</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Average cLog<ce:italic>P</ce:italic>: <ce:inter-ref xlink:href="http://146.107.217.178/lab/alogps/start.html" id="intref0020" xlink:type="simple">http://146.107.217.178/lab/alogps/start.html</ce:inter-ref>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0020" view="all">tPSA: <ce:inter-ref xlink:href="http://www.molinspiration.com/cgi-bin/properties" id="intref0025" xlink:type="simple">http://www.molinspiration.com/cgi-bin/properties</ce:inter-ref>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0025" view="all">Breast cancer cell lines: MCF-7 and MDA-MB-231. Pancreatic cancer cell lines: AsPC1 and Panc-1. Software: MasterPlex ReaderFit 2010, MiraiBio, Inc.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0030" view="all">If a specific compound is given a value >10, it indicates that a specific IC<ce:inf loc="post">50</ce:inf> cannot be calculated from the data points collected, meaning ‘no effect’.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fne">
                  <ce:label>e</ce:label>
                  <ce:note-para id="ntpara0035" view="all">ND: not determined.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Original article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Discovery of potent anticancer agent <ce:bold>HJC0416</ce:bold>, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1">
                  <ce:given-name>Haijun</ce:given-name>
                  <ce:surname>Chen</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="aff3" id="crosref0015">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0020">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2">
                  <ce:given-name>Zhengduo</ce:given-name>
                  <ce:surname>Yang</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0025">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0030">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3">
                  <ce:given-name>Chunyong</ce:given-name>
                  <ce:surname>Ding</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0035">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4">
                  <ce:given-name>Ailian</ce:given-name>
                  <ce:surname>Xiong</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0040">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5">
                  <ce:given-name>Christopher</ce:given-name>
                  <ce:surname>Wild</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0045">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6">
                  <ce:given-name>Lili</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0050">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7">
                  <ce:given-name>Na</ce:given-name>
                  <ce:surname>Ye</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0055">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8">
                  <ce:given-name>Guoshuai</ce:given-name>
                  <ce:surname>Cai</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0060">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9">
                  <ce:given-name>Rudolfo M.</ce:given-name>
                  <ce:surname>Flores</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0065">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10">
                  <ce:given-name>Ye</ce:given-name>
                  <ce:surname>Ding</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0070">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au11">
                  <ce:given-name>Qiang</ce:given-name>
                  <ce:surname>Shen</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0075">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0080">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au12">
                  <ce:given-name>Jia</ce:given-name>
                  <ce:surname>Zhou</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0085">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0090">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, United States</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Chemical Biology Program</sa:organization>
                     <sa:organization>Department of Pharmacology and Toxicology</sa:organization>
                     <sa:organization>University of Texas Medical Branch</sa:organization>
                     <sa:city>Galveston</sa:city>
                     <sa:state>TX</sa:state>
                     <sa:postal-code>77555</sa:postal-code>
                     <sa:country>United States</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff2">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Clinical Cancer Prevention</sa:organization>
                     <sa:organization>Division of Cancer Prevention and Population Sciences</sa:organization>
                     <sa:organization>The University of Texas M.D. Anderson Cancer Center</sa:organization>
                     <sa:city>Houston</sa:city>
                     <sa:state>TX</sa:state>
                     <sa:postal-code>77030</sa:postal-code>
                     <sa:country>United States</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff3">
                  <ce:label>c</ce:label>
                  <ce:textfn>College of Chemistry and Chemical Engineering, Fuzhou University, Fuzhou, Fujian 350002, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>College of Chemistry and Chemical Engineering</sa:organization>
                     <sa:organization>Fuzhou University</sa:organization>
                     <sa:city>Fuzhou</sa:city>
                     <sa:state>Fujian</sa:state>
                     <sa:postal-code>350002</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding authors.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contribute equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="10" month="3" year="2014"/></ce:date-received>
            <ce:date-revised day="15" month="5" year="2014"/></ce:date-revised>
            <ce:date-accepted day="21" month="5" year="2014"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">In a continuing effort to develop orally bioavailable small-molecule STAT3 inhibitors as potential therapeutic agents for human cancer, a series of novel diversified analogues based on our identified lead compound <ce:bold>HJC0149</ce:bold> (<ce:bold>1</ce:bold>) (5-chloro-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-hydroxybenzamide, <ce:italic>Eur. J. Med. Chem</ce:italic>. <ce:bold>2013</ce:bold>, <ce:italic>62</ce:italic>, 498–507) have been rationally designed, synthesized, and pharmacologically evaluated. Molecular docking studies and biological characterization supported our earlier findings that the <ce:italic>O</ce:italic>-alkylamino-tethered side chain on the hydroxyl group is an effective and essential structural determinant for improving biological activities and druglike properties of these molecules. Compounds with such modifications exhibited potent antiproliferative effects against breast and pancreatic cancer cell lines with IC<ce:inf loc="post">50</ce:inf> values from low micromolar to nanomolar range. Among them, the newly discovered STAT3 inhibitor <ce:bold>12</ce:bold> (<ce:bold>HJC0416</ce:bold>) displayed an intriguing anticancer profile both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> (i.p. & p.o.). More importantly, <ce:bold>HJC0416</ce:bold> is an orally bioavailable anticancer agent as a promising candidate for further development.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:link locator="fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>STAT3 inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Oral bioavailability</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Breast cancer</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Pancreatic cancer</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Anticancer agents</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Signal transducer and activator of transcription 3 (STAT3) is the most studied member of a family of seven proteins (STAT1, 2, 3, 4, 5a, 5b, and 6) that are involved in the regulation of early embryonic development, angiogenesis, immune response, cell proliferation, differentiation, and apoptosis <ce:cross-refs refid="bib1 bib2 bib3 bib4 bib5" id="crosrefs0010">[1–5]</ce:cross-refs>. From nearly two decades of research on STAT3, accumulating evidence has demonstrated that STAT3 is hyperactivated in many human tumors and represents an attractive therapeutic target for the treatment of various types of cancer <ce:cross-refs refid="bib6 bib7 bib8 bib9 bib10 bib11 bib12" id="crosrefs0015">[6–12]</ce:cross-refs>. However, despite many years of intensive research devoted to the discovery of small molecules targeting STAT3, only several compounds are in early phase clinical trials, and currently there are no candidates approved for clinical use in oncology <ce:cross-refs refid="bib13 bib14 bib15" id="crosrefs0020">[13–15]</ce:cross-refs>. The suitability of the scaffolds and physicochemical properties are most significant issues in promoting a potent agent into clinical trials <ce:cross-ref refid="bib16" id="crosref0095">[16]</ce:cross-ref>. Thus, there is an urgent need to develop novel diversified scaffolds, and orally bioavailable drug candidates capable of targeting STAT3 <ce:cross-ref refid="bib17" id="crosref0100">[17]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0035" view="all">Our previous work by utilizing fragment-based drug design (FBDD) approach has explored several novel scaffolds targeting STAT3 as potent anticancer agents <ce:cross-ref refid="bib18" id="crosref0105">[18]</ce:cross-ref>. The identified drug candidates including <ce:bold>HJC0149</ce:bold> (<ce:bold>1</ce:bold>) with enhanced pharmacological activities and especially drug-like properties may act as advanced chemical leads for further optimization (<ce:cross-ref refid="fig1" id="crosref0110">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>) <ce:cross-ref refid="bib18" id="crosref0115">[18]</ce:cross-ref>. Another previous effort in our laboratories has demonstrated that it is feasible to identify new niclosamide derivatives with improved oral bioavailability through modifications of the hydroxyl group on the phenol ring tethered by an <ce:italic>O</ce:italic>-alkylamino side chain, leading to the identification of <ce:bold>HJC0152</ce:bold> with a similar or significantly higher anticancer potency on proliferation of human breast and pancreatic cancer cells <ce:cross-ref refid="bib19" id="crosref0120">[19]</ce:cross-ref>. Pharmacological evaluation revealed that <ce:bold>HJC0152</ce:bold> inhibited STAT3 promoter activity, and increased the expression of active caspase-3. Further <ce:italic>in vivo</ce:italic> studies in nude mice bearing triple-negative breast tumor xenografts demonstrated that <ce:bold>HJC0152</ce:bold> significantly suppressed tumor growth (both i.p. & p.o.) <ce:cross-ref refid="bib19" id="crosref0125">[19]</ce:cross-ref>. These results suggest that chemical optimization of the hydroxyl group of salicylic amide scaffold in niclosamide may be a viable strategy to develop novel orally bioavailable agents for human cancer therapy.</ce:para>
                  <ce:para id="p0040" view="all">In a continuing effort to develop novel diversified analogues based on the scaffold of lead compound <ce:bold>1</ce:bold>, we directed our chemical optimization involving modification of the hydroxyl group on the phenol ring by introduction of <ce:italic>O</ce:italic>-alkylamino side chains as depicted in <ce:cross-ref refid="fig1" id="crosref0130">Fig. 1</ce:cross-ref>. We envisioned that such modifications on the salicylic amide moiety of <ce:bold>1</ce:bold> by utilizing the same strategy might enhance both anticancer potency and oral bioavailability. Herein, we report the lead optimization of compound <ce:bold>1</ce:bold> with a focus on improving anticancer activity and bioavailability. These studies led to the discovery of an orally efficacious anticancer agent <ce:bold>12</ce:bold> (<ce:bold>HJC0416</ce:bold>), a promising candidate for further drug development.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0045" view="all">The synthesis of new derivatives based on salicylic amide scaffold with chemical optimization of the hydroxyl group is outlined in <ce:cross-ref refid="sch1" id="crosref0135">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>. Analogues <ce:bold>2</ce:bold>–<ce:bold>6</ce:bold> were conveniently prepared by Mitsunobu reaction of the appropriate substituted alcohols with lead compound <ce:bold>1</ce:bold> in 39–77% yields. Alkylation of the bromide intermediate <ce:bold>2</ce:bold> with piperidine or 1-methylpiperazine in the presence of K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> and KI in acetone introduced basic functionalities into the molecules providing compounds <ce:bold>7</ce:bold> and <ce:bold>8</ce:bold> in yield of 98% and 77%, respectively. Mitsunobu coupling of lead compound <ce:bold>1</ce:bold> with <ce:italic>N</ce:italic>-Boc-protected amino alcohols followed by the Boc-deprotection with the treatment of TFA afforded analogues <ce:bold>9</ce:bold>–<ce:bold>13</ce:bold> with diversified <ce:italic>O</ce:italic>-alkylamino side chains in 40–52% yields (two steps). Modification of benzo[<ce:italic>b</ce:italic>]thiophene 1,1-dioxide motif by introducing an ether group to the double bond moiety is shown in <ce:cross-ref refid="sch2" id="crosref0140">Scheme 2</ce:cross-ref>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>. Compound <ce:bold>14</ce:bold> was prepared from <ce:bold>1</ce:bold> by the treatment with methanol and 10% aqueous solution of NaOH in yield of 60% <ce:cross-ref refid="bib20" id="crosref0145">[20]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Biology</ce:section-title>
                     <ce:para id="p0050" view="all">To explore the structure–activity relationship (SAR) and examine how the substitutions of the moiety groups affected biological activities of newly synthesized analogues, we first evaluated the <ce:italic>in vitro</ce:italic> anticancer effects of compounds <ce:bold>2</ce:bold>–<ce:bold>14</ce:bold> on the proliferation of breast cancer cell lines MCF-7 (ER-positive) and MDA-MB-231 (ER-negative and triple-negative), as well as two pancreatic cancer cell lines AsPC1 and Panc-1 using MTS assays as described in the Experimental Section. The suitable calculated lipophilicity (cLog<ce:italic>P</ce:italic>) and topological polar surface area (tPSA) values shown in <ce:cross-ref refid="tbl1" id="crosref0150">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor> suggest that these newly designed analogues are clearly in good alignment with Lipinski's “Rule of Five” and may have ideal physicochemical properties. Meanwhile, the introduced basic functionalities of the target molecules can form HCl salts to facilitate the aqueous solubility. The capabilities of these new analogues to inhibit the growth of cancer cells are summarized in <ce:cross-ref refid="tbl1" id="crosref0155">Table 1</ce:cross-ref>. Introduction of an <ce:italic>O</ce:italic>-bromoalkyl group into the lead compound <ce:bold>1</ce:bold> resulted in a dramatic loss of activity, and the derivative <ce:bold>2</ce:bold> displayed no significant antiproliferative effects on all tested cell lines. However, further replacement of the bromo with a hydrophilic amino group regained the antiproliferative effects to a similar or significantly enhanced level in comparison with <ce:bold>1</ce:bold>. For instance, <ce:italic>O</ce:italic>-alkylamino-tethered derivatives <ce:bold>4</ce:bold>–<ce:bold>13</ce:bold> exhibited promising antiproliferative effects against four cancer cell lines with IC<ce:inf loc="post">50</ce:inf> values from low micromolar to nanomolar range. Compound <ce:bold>6</ce:bold> with a morpholine moiety showed potent antiproliferative effect against MCF-7 with an IC<ce:inf loc="post">50</ce:inf> value of 0.49 μM. Compound <ce:bold>12</ce:bold> inhibited the proliferation of both ER-positive, and ER-negative (triple negative) breast cancer cells with IC<ce:inf loc="post">50</ce:inf> values of 1.76 μM and 1.97 μM, respectively. Intriguingly, compound <ce:bold>12</ce:bold> also displayed a marked antiproliferative effect against pancreatic cancer cell line AsPC1 with an IC<ce:inf loc="post">50</ce:inf> value of 40 nM. Interestingly, the fluorinated derivative <ce:bold>3</ce:bold> displayed moderate to potent antiproliferative effects against the tested cancer cells, indicating that this compound might be suitable for developing as a potential <ce:sup loc="pre">18</ce:sup>F-radiolabeled positron emission tomography (PET) imaging agent for human cancer <ce:cross-ref refid="bib21" id="crosref0160">[21]</ce:cross-ref>. Modification of benzo[<ce:italic>b</ce:italic>]thiophene 1,1-dioxide motif by introducing an ether group to the double bond moiety has been demonstrated to generally reduce the antiproliferative effects. For example, compound <ce:bold>14</ce:bold> displayed only moderate activity against all the tested cell lines, indicating that benzo[<ce:italic>b</ce:italic>]thiophene 1,1-dioxide is an important pharmacophore for this class of molecules. Therefore, more extensive SAR study based upon the scaffold of compound <ce:bold>14</ce:bold> was not pursued.</ce:para>
                     <ce:para id="p0055" view="all">Among the newly synthesized analogs, compound <ce:bold>12</ce:bold> was selected for a battery of further <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> characterizations due to its enhanced antiproliferative effects and druglike properties including the aqueous solubility. To further study the anticancer effects of compound <ce:bold>12</ce:bold> on cell growth, cellular morphological changes were examined in MDA-MB-231 breast cancer cells treated with compound <ce:bold>12</ce:bold> or stattic for 48 h, under light microscopy. As shown in <ce:cross-ref refid="fig2" id="crosref0165">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>, like stattic, <ce:bold>12</ce:bold> significantly inhibited cell growth and induced apoptosis accompanying cellular morphological changes at concentration of 1 μM, 5 μM, and 10 μM, respectively.</ce:para>
                     <ce:para id="p0060" view="all">To determine whether compound <ce:bold>12</ce:bold> acts as a potent small-molecule inhibitor of STAT3 activation, we further measured the inhibitory effect on promoter activity using the cell-based transient transfection and dual luciferase reporter assays. MDA-MB-231 cells were pre-treated with stattic or <ce:bold>12</ce:bold> at the same concentration (5 μM) for 24 h. The STAT3 promoter activity in MDA-MB-231 cells was determined after transient transfecting with pSTAT3-Luc vector. As shown in <ce:cross-ref refid="fig3" id="crosref0170">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>, treatment with 5 μM of <ce:bold>12</ce:bold> decreased the STAT3 promoter activity in MDA-MB-231 cells by approximately 51%, while stattic only decreased the STAT3 promoter activity by 39%.</ce:para>
                     <ce:para id="p0065" view="all">Our previous work and studies from other groups have revealed that compounds with the 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl fragment might interact with STAT3-SH2 domain <ce:cross-refs refid="bib18 bib22" id="crosrefs0025">[18,22]</ce:cross-refs>. In an attempt to elucidate the structural basis of the inhibition of STAT3 assembly at the SH2 binding site, it was of interest to determine the possible conformation and binding pose of compound <ce:bold>12</ce:bold> by using AutoDock Vina docking approach <ce:cross-refs refid="bib18 bib23" id="crosrefs0030">[18,23]</ce:cross-refs>. As depicted in <ce:cross-ref refid="fig4" id="crosref0175">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>, the 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl moiety interacted with the pocket of Val637 and Ile659 in a similar fashion as we previously reported <ce:cross-ref refid="bib18" id="crosref0180">[18]</ce:cross-ref>. The salicylic amide of compound <ce:bold>1</ce:bold> and compound <ce:bold>12</ce:bold> formed the H-bond with Trp623, while oxygen of 3-aminopropoxy side chain of <ce:bold>12</ce:bold> formed an additional H-bond with Trp623 and terminal amino group formed another H-bond with Glu638. Furthermore, the alkyl chain might have the hydrophobic interactions with Val637. These molecular docking studies could also reasonably explain why the compounds with a hydrophilic amino group or the certain length of the carbon chain might have better anticancer activity. It is worth mentioning that the large pocket formed around Lys591, Glu594, Arg595, Arg609 and Glu612 may be a good starting point for further drug design and structural optimization.</ce:para>
                     <ce:para id="p0070" view="all">To further investigate the inhibitory activity of compound <ce:bold>12</ce:bold> against STAT3 pathway, we examined STAT3 phosphorylation and expression of the known STAT3 target genes in MDA-MB-231 cell line. The cells were treated with different doses of compound <ce:bold>12</ce:bold> for 12 h, and levels of total STAT3 and phosphorylated STAT3 at Tyr-705 were then examined by Western blot. As shown in <ce:cross-ref refid="fig5" id="crosref0185">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>, total STAT3 expression in these cells was reduced after treatment with compound <ce:bold>12</ce:bold> or stattic. Similarly, phosphorylated STAT3 at Tyr-705 is suppressed by compound <ce:bold>12</ce:bold> or stattic, suggesting that compound <ce:bold>12</ce:bold> has a comparable potency in downregulating STAT3 protein production and phosphorylation at Tyr-705 site. We observed that compound <ce:bold>12</ce:bold> induced cleaved caspase-3 and downregulated cyclin D1 levels in MDA-MB-231 cells. These results suggest that compound <ce:bold>12</ce:bold> inhibits cell cycle progression and promotes apoptosis.</ce:para>
                     <ce:para id="p0075" view="all">Compound <ce:bold>12</ce:bold> was further evaluated for potential antitumor effects in the MDA-MB-231 triple-negative breast cancer murine xenograft model, and tumor volume was measured daily in intraperitoneal treatment (i.p.) and oral gavage (p.o.) groups. It was found that mice treated with 10 mg/kg of compound <ce:bold>12</ce:bold> via i.p. showed a 67% decrease of tumor volume as compared to the control mice (<ce:cross-ref refid="fig6" id="crosref0190">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>A). Similarly, we treated the MDA-MB-231 xenograft mice with oral administration of compound <ce:bold>12</ce:bold> and found that the growth of xenograft tumors in mice was also significantly reduced at a dose of 100 mg/kg by 46% (<ce:cross-ref refid="fig6" id="crosref0195">Fig. 6</ce:cross-ref>B). The i.p. route appeared to have a better reduction of tumor volume, and this observation might be attributed to the efficiency of bioavailability for compound <ce:bold>12.</ce:bold> It is also noteworthy that compound <ce:bold>12</ce:bold> did not show significant signs of toxicity at a dose of 100 mg/kg. These results have demonstrated that compound <ce:bold>12</ce:bold> effectively reduced the tumor growth originated from MDA-MB-231 cells <ce:italic>in vivo</ce:italic> with no significant body weight loss, indicating its low adverse side effects as a drug candidate. Further pharmacokinetic studies and preclinical assessment are under way.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0050">Conclusions</ce:section-title>
                  <ce:para id="p0080" view="all">In summary, an appropriate modification of the hydroxyl group of salicylic amide scaffold enabled us to expand the scope of the exploration of the series, leading to the identification of several potent STAT3 inhibitors with enhanced anticancer activities and druglike properties. Through the optimization of the lead compound <ce:bold>1</ce:bold>, a novel <ce:italic>O</ce:italic>-alkylamino-tethered derivative <ce:bold>12</ce:bold> has been discovered to exhibit potent antiproliferative effects, inhibit STAT3 promoter activity, and decrease the expression of phosphorylated STAT3. Molecular docking studies support our findings that the <ce:italic>O</ce:italic>-alkylamino side chain on the hydroxyl group of this class of compounds is an effective and essential structural determinant for improving biological activity and druglikeness. Intriguingly, <ce:bold>12</ce:bold> significantly suppressed MDA-MB-231 xenograft tumor growth <ce:italic>in vivo</ce:italic> (i.p. & p.o.), indicating its great potential as an orally bioavailable anticancer agent. This work together with our previous efforts enabled us to establish a sizable compound library of druglike STAT3 inhibitors with diversified scaffolds and may open new venues for further clinical development of promising candidates for human cancer therapeutic regimens.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0055">Experimental section</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0060">Chemistry</ce:section-title>
                     <ce:para id="p0085" view="all">All commercially available starting materials and solvents were reagent grade, and used without further purification. Reactions were performed under a nitrogen atmosphere in dry glassware with magnetic stirring. Preparative column chromatography was performed using silica gel 60, particle size 0.063–0.200 mm (70–230 mesh, flash). Analytical TLC was carried out employing silica gel 60 F254 plates (Merck, Darmstadt). Visualization of the developed chromatograms was performed with detection by UV (254 nm). NMR spectra were recorded on a Bruker-600 (<ce:sup loc="pre">1</ce:sup>H, 600 MHz; <ce:sup loc="pre">13</ce:sup>C, 150 MHz) spectrometer. <ce:sup loc="pre">1</ce:sup>H and <ce:sup loc="pre">13</ce:sup>C NMR spectra were recorded with TMS as an internal reference. Chemical shifts were expressed in ppm, and <ce:italic>J</ce:italic> values were given in Hz. High-resolution mass spectra (HRMS) were obtained from Thermo Fisher LTQ Orbitrap Elite mass spectrometer. Parameters include the following: Nano ESI spray voltage was 1.8 kV; Capillary temperature was 275 °C and the resolution was 60,000; Ionization was achieved by positive mode. Melting points were measured on a Thermo Scientific Electrothermal Digital Melting Point Apparatus and uncorrected. Purity of final compounds was determined by analytical HPLC, which was carried out on a Shimadzu HPLC system (model: CBM-20A LC-20AD SPD-20A UV/VIS). HPLC analysis conditions: Waters μBondapak C18 (300 × 3.9 mm); flow rate 0.5 mL/min; UV detection at 270 and 254 nm; linear gradient from 30% acetonitrile in water (0.1% TFA) to 100% acetonitrile (0.1% TFA) in 20 min followed by 30 min of the last-named solvent. All biologically evaluated compounds are >95% pure.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0065">2-(2-Bromoethoxy)-5-chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)benzamide (<ce:bold>2</ce:bold>)</ce:section-title>
                        <ce:para id="p0090" view="all">To a solution of 5-chloro-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-hydroxybenzamide (<ce:bold>1</ce:bold>, <ce:bold>HJC0149</ce:bold>) <ce:cross-ref refid="bib18" id="crosref0200">[18]</ce:cross-ref> (200 mg, 0.6 mmol) and PPh<ce:inf loc="post">3</ce:inf> (314 mg, 1.2 mmol) in THF (5 mL) was added 2-bromoethanol (150 mg, 1.2 mmol) and DIAD (218 mg, 1.08 mmol). The mixture was stirred at r.t. for 16 h. The reaction mixture was diluted with EtOAc (100 mL) and extracted with H<ce:inf loc="post">2</ce:inf>O (40 mL). The organic layer was washed with brine (10 mL), dried with anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, and then concentrated to give the crude product. This residue was purified with silica gel column (Hexane/Acetone = 2/1 to 1/2) to provide <ce:bold>2</ce:bold> (200 mg, 75%) as a yellow solid (mp 235–236 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.59 (s, 1H), 8.26 (s, 1H), 7.89 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.70 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.58–7.61 (m, 3H), 7.26–7.31 (m, 2H), 4.47 (t, 2H, <ce:italic>J</ce:italic> = 5.4 Hz), 3.87 (t, 2H, <ce:italic>J</ce:italic> = 5.4 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.4, 154.1, 141.1, 137.2, 132.8, 132.0, 130.2, 129.3, 126.5, 126.2, 125.9, 125.0, 123.9, 115.5, 112.0, 69.1, 31.1. HRMS (ESI) calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">14</ce:inf>BrClNO<ce:inf loc="post">4</ce:inf>S 441.9510 (M + H)<ce:sup loc="post">+</ce:sup>, found 441.9515.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0070">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-fluoroethoxy)benzamide (<ce:bold>3</ce:bold>)</ce:section-title>
                        <ce:para id="p0095" view="all">Compound <ce:bold>3</ce:bold> was prepared in 77% yield by a procedure similar to that used to prepare compound <ce:bold>2</ce:bold>. The title compound was obtained as a pale yellow solid (mp 216–217 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.63 (s, 1H), 8.21 (s, 1H), 7.85–7.86 (m, 1H), 7.68 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.58–7.61 (m, 3H), 7.26–7.31 (m, 2H), 4.74–4.83 (m, 2H), 4.37–4.43 (m, 2H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.6, 154.3, 141.1, 137.2, 132.8, 131.9, 130.2, 129.1, 126.6, 126.4, 125.9, 124.9, 123.7, 115.5, 111.7, 82.1 (d, <ce:italic>J</ce:italic> = 166 Hz), 68.5 (d, <ce:italic>J</ce:italic> = 18 Hz). HRMS (ESI) calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">14</ce:inf>ClFNO<ce:inf loc="post">4</ce:inf>S 382.0311 (M + H)<ce:sup loc="post">+</ce:sup>, found 382.0314.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0075">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(1-methylpiperidin-4-yloxy) benzamide (<ce:bold>4</ce:bold>)</ce:section-title>
                        <ce:para id="p0100" view="all">Compound <ce:bold>4</ce:bold> was prepared in 39% yield by a procedure similar to that used to prepare compound <ce:bold>2</ce:bold>. The title compound was obtained as a pale yellow solid (mp 220–221 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.63 (s, 1H), 8.22 (s, 1H), 7.85 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.58–7.61 (m, 3H), 7.51–7.53 (m, 1H), 7.27–7.30 (m, 2H), 4.53–4.55 (m, 1H), 2.42–2.44 (m, 2H), 2.19–2.21 (m, 2H), 2.06 (s, 3H), 1.89–1.91 (m, 2H), 1.69–1.71 (m, 2H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 164.1, 153.2, 141.2, 137.2, 132.8, 131.5, 130.1, 128.8, 128.0, 126.6, 125.8, 124.4, 123.5, 116.8, 111.6, 79.2, 51.6, 45.8, 30.0. HRMS (ESI) calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">22</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S 433.0983 (M + H)<ce:sup loc="post">+</ce:sup>, found 433.0989.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0080">5-Chloro-2-(2-dimethylamino-ethoxy)-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl) benzamide (<ce:bold>5</ce:bold>)</ce:section-title>
                        <ce:para id="p0105" view="all">Compound <ce:bold>5</ce:bold> was prepared in 62% yield by a procedure similar to that used to prepare compound <ce:bold>2</ce:bold>. The title compound was obtained as a pale yellow solid (mp 189–190 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.77 (s, 1H), 8.41 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.24 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 7.99 (s, 1H), 7.43–7.45 (m, 1H), 7.33 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.20 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 6.97 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 6.64 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 4.26 (t, 2H, <ce:italic>J</ce:italic> = 5.4 Hz), 2.84 (t, 2H, <ce:italic>J</ce:italic> = 4.2 Hz), 2.39 (s, 6H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 162.4, 155.3, 141.9, 137.6, 133.4, 132.5, 132.5, 129.7, 127.5, 126.0, 124.5, 123.0, 114.3, 66.1, 57.9, 45.2. HRMS (ESI) calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">20</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S 407.0827 (M + H)<ce:sup loc="post">+</ce:sup>, found 407.0831.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0085">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-morpholin-4-yl-ethoxy) benzamide (<ce:bold>6</ce:bold>)</ce:section-title>
                        <ce:para id="p0110" view="all">Compound <ce:bold>6</ce:bold> was prepared in 67% yield by a procedure similar to that used to prepare compound <ce:bold>2</ce:bold>. The title compound was obtained as a white solid (mp 214–215 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.72 (s, 1H), 8.18 (s, 1H), 7.90 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.73 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.58–7.62 (m, 3H), 7.27–7.32 (m, 2H), 4.26–4.28 (m, 2H), 3.43–3.45 (m, 4H), 2.74–2.76 (m, 2H), 2.42–2.50 (m, 4H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.4, 154.8, 141.0, 137.2, 132.8, 132.1, 130.2, 129.2, 126.5, 126.0, 125.5, 124.7, 124.1, 115.4, 112.1, 66.7, 66.0, 56.6, 53.3. HRMS (ESI) calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">22</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>S 449.0932 (M + H)<ce:sup loc="post">+</ce:sup>, found 449.0942.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title id="sectitle0090">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-piperidin-1-yl-ethoxy)benzamide (<ce:bold>7</ce:bold>)</ce:section-title>
                        <ce:para id="p0115" view="all">To a solution of <ce:bold>2</ce:bold> (50 mg, 0.11 mmol), KI (28 mg, 0.17 mmol) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (32 mg, 0.23 mmol) in acetone (5 mL) was added piperidine (49 mg, 0.57 mmol) at 0 <ce:sup loc="pre">°</ce:sup>C. The mixture was stirred at 75 <ce:sup loc="pre">°</ce:sup>C for 18 h. The solution was diluted with EtOAc (100 mL), washed with 0.1 N HCl (aq.) (10 mL) and brine (10 mL). The organic layer was dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1/1 to 1/3) to give the desired product <ce:bold>7</ce:bold> (50 mg, 98%) as a pale yellow solid (mp 180–181 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.71 (s, 1H), 8.20 (s, 1H), 7.89 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.74 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.59–7.62 (m, 3H), 7.27–7.31 (m, 2H), 4.25 (t, 2H, <ce:italic>J</ce:italic> = 5.4 Hz), 2.70–2.72 (m, 2H), 2.38–2.40 (m, 4H), 1.35–1.38 (m, 4H), 1.22–1.24 (m, 2H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.3, 155.0, 141.0, 137.2, 132.8, 132.2, 130.2, 129.3, 126.5, 126.0, 125.3, 124.7, 124.1, 115.4, 112.2, 66.9, 56.9, 54.1, 25.4, 23.8. HRMS (ESI) calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">24</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S 447.1140 (M + H)<ce:sup loc="post">+</ce:sup>, found 447.1145.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.7" view="all">
                        <ce:label>4.1.7</ce:label>
                        <ce:section-title id="sectitle0095">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-[2-(4-methylpiperazin-1-yl)-ethoxy]benzamide (<ce:bold>8</ce:bold>)</ce:section-title>
                        <ce:para id="p0120" view="all">Compound <ce:bold>8</ce:bold> was prepared in 77% yield by a procedure similar to that used to prepare compound <ce:bold>7</ce:bold>. The title compound was obtained as a pale yellow solid (mp 218–219 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.70 (s, 1H), 8.17 (s, 1H), 7.89–7.90 (m, 1H), 7.73 (d, 1H, <ce:italic>J</ce:italic> = 3.0 Hz), 7.58–7.62 (m, 3H), 7.26–7.31 (m, 2H), 4.25 (t, 2H, <ce:italic>J</ce:italic> = 5.4 Hz), 2.73 (t, 2H, <ce:italic>J</ce:italic> = 4.8 Hz), 2.42–2.50 (m, 4H), 2.12–2.22 (m, 4H), 2.03 (s, 3H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.3, 154.9, 141.0, 137.2, 132.8, 132.2, 130.2, 129.2, 126.5, 126.0, 125.4, 124.7, 124.2, 115.4, 112.2, 66.9, 56.2, 54.5, 52.7, 45.6. HRMS (ESI) calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S 462.1249 (M + H)<ce:sup loc="post">+</ce:sup>, found 462.1253.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.8" view="all">
                        <ce:label>4.1.8</ce:label>
                        <ce:section-title id="sectitle0100">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-piperazin-1-yl-ethoxy) benzamide (<ce:bold>9</ce:bold>)</ce:section-title>
                        <ce:para id="p0125" view="all">To a solution of 5-chloro-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-hydroxybenzamide (100 mg, 0.3 mmol) and PPh<ce:inf loc="post">3</ce:inf> (157 mg, 0.6 mmol) in THF (5 mL) was added 4-(2-hydroxyethyl)-piperazine-1-carboxylic acid <ce:italic>tert</ce:italic>-butyl ester (138 mg, 0.6 mmol) in THF (5 mL) and DIAD (109 mg, 0.54 mmol). The mixture was stirred at r.t. for 2 h, and then was concentrated to give the crude product. This residue was purified with silica gel column (EtOAc/hexane = 1/1) to afford 80 mg of the intermediate as a pale yellow solid. To the solution of the intermediate (80 mg) in CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (5 mL) was added TFA (1 mL) at 0 <ce:sup loc="pre">°</ce:sup>C. The mixture was stirred at r.t. for 3 h, and then was concentrated. The residue was partitioned between EtOAc (250 mL) and 1 N NaHCO<ce:inf loc="post">3</ce:inf> (10 mL). The organic layer was washed with H<ce:inf loc="post">2</ce:inf>O (10 mL) and dried with Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The organic layer was concentrated. The residue was washed with EtOAc (10 mL) and then the solid was filtered to give <ce:bold>9</ce:bold> (65 mg, 48%, two steps) as a pale yellow solid (mp 206–207 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.71 (s, 1H), 8.52 (s, 1H), 8.21 (s, 1H), 7.87–7.89 (m, 1H), 7.69 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.58–7.63 (m, 3H), 7.32 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.26 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 4.24 (t, 2H, <ce:italic>J</ce:italic> = 4.8 Hz), 2.96 (t, 4H, <ce:italic>J</ce:italic> = 4.8 Hz), 2.82 (t, 2H, <ce:italic>J</ce:italic> = 4.8 Hz), 2.62–2.64 (m, 4H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.6, 154.6, 141.1, 137.2, 132.9, 132.0, 130.2, 129.1, 126.6, 126.0, 126.0, 124.6, 123.8, 115.2, 111.9, 66.9, 55.8, 49.4, 42.9. HRMS (ESI) calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">23</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S 448.1092 (M + H)<ce:sup loc="post">+</ce:sup>, found 448.1101.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.9" view="all">
                        <ce:label>4.1.9</ce:label>
                        <ce:section-title id="sectitle0105">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(piperidin-4-yloxy)benzamide (<ce:bold>10</ce:bold>)</ce:section-title>
                        <ce:para id="p0130" view="all">Compound <ce:bold>10</ce:bold> was prepared in 52% yield by a procedure similar to that used to prepare compound <ce:bold>9</ce:bold>. The title compound was obtained as a pale yellow solid (mp 128–129 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.73 (s, 1H), 8.26 (s, 1H), 7.81–7.82 (m, 1H), 7.58–7.63 (m, 3H), 7.54–7.61 (m, 1H), 7.29–7.31 (m, 2H), 4.72–4.73 (m, 1H), 3.03–3.07 (m, 2H), 2.87–2.90 (m, 2H), 1.98–2.01 (m, 2H), 1.74–1.77 (m, 2H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 164.2, 152.8, 141.3, 137.2, 132.9, 131.4, 130.2, 128.9, 128.2, 126.6, 125.9, 124.6, 123.6, 116.7, 111.6, 71.7, 41.1, 28.5. HRMS (ESI) calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">20</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S 419.0827 (M + H)<ce:sup loc="post">+</ce:sup>, found 419.0834.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.10" view="all">
                        <ce:label>4.1.10</ce:label>
                        <ce:section-title id="sectitle0110">2-(2-Aminoethoxy)-5-chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)benzamide (<ce:bold>11</ce:bold>)</ce:section-title>
                        <ce:para id="p0135" view="all">Compound <ce:bold>11</ce:bold> was prepared in 40% yield by a procedure similar to that used to prepare compound <ce:bold>9</ce:bold>. The title compound was obtained as a pale yellow solid (mp 202–203 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, acetone-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.85 (s, 1H), 8.19 (s, 1H), 8.13–8.15 (m, 1H), 8.06 (d, 1H, <ce:italic>J</ce:italic> = 3.0 Hz), 7.55–7.59 (m, 2H), 7.51–7.52 (m, 1H), 7.33 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 6.99 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 4.52 (t, 2H, <ce:italic>J</ce:italic> = 4.8 Hz), 3.80 (t, 2H, <ce:italic>J</ce:italic> = 4.8 Hz), 1.92–1.96 (m, 2H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.4, 154.8, 141.2, 137.1, 132.6, 132.1, 130.1, 129.5, 126.4, 125.8, 125.8, 124.6, 124.1, 116.0, 112.1, 71.2, 40.4. HRMS (ESI) calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">16</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S 379.0514 (M + H)<ce:sup loc="post">+</ce:sup>, found 379.0520.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.11" view="all">
                        <ce:label>4.1.11</ce:label>
                        <ce:section-title id="sectitle0115">2-(3-Aminopropoxy)-5-chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)benzamide (<ce:bold>12</ce:bold>)</ce:section-title>
                        <ce:para id="p0140" view="all">Compound <ce:bold>12</ce:bold> was prepared in 51% yield by a procedure similar to that used to prepare compound <ce:bold>9</ce:bold>. The title compound was obtained as a pale yellow solid (mp 115–116 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.76 (s, 1H), 8.31 (s, 1H), 7.78–7.80 (m, 1H), 7.75 (s, 2H), 7.57–7.64 (m, 4H), 7.31 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 7.21 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 4.18 (t, 2H, <ce:italic>J</ce:italic> = 6.0 Hz), 2.95 (t, 2H, <ce:italic>J</ce:italic> = 6.6 Hz), 2.00–2.02 (m, 2H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 164.3, 154.3, 141.3, 137.2, 132.8, 131.6, 130.2, 128.8, 126.8, 126.6, 125.9, 124.3, 123.8, 114.8, 111.8, 66.0, 36.5, 26.5. HRMS (ESI) calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">18</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S 393.0670 (M + H)<ce:sup loc="post">+</ce:sup>, found 393.0678.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.12" view="all">
                        <ce:label>4.1.12</ce:label>
                        <ce:section-title id="sectitle0120">5-Chloro-N-(1,1-dioxo-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-(2-methylaminoethoxy)benzamide (<ce:bold>13</ce:bold>)</ce:section-title>
                        <ce:para id="p0145" view="all">Compound <ce:bold>13</ce:bold> was prepared in 43% yield by a procedure similar to that used to prepare compound <ce:bold>9</ce:bold>. The title compound was obtained as a white solid (mp 175–176 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.77 (s, 1H), 8.36–8.38 (m, 1H), 8.21 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.10 (s, 1H), 7.44–7.46 (m, 1H), 7.35 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.21–7.22 (m, 1H), 6.98 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 6.67 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 4.31 (t, 2H, <ce:italic>J</ce:italic> = 4.8 Hz), 3.18 (t, 2H, <ce:italic>J</ce:italic> = 5.4 Hz), 2.64 (s, 3H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 162.6, 155.2, 141.8, 137.6, 133.3, 132.5, 132.4, 129.6, 127.4, 126.0, 124.5, 123.3, 114.3, 114.1, 68.3, 50.8, 36.5. HRMS (ESI) calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">18</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S 393.0670 (M + H)<ce:sup loc="post">+</ce:sup>, found 393.0678.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.13" view="all">
                        <ce:label>4.1.13</ce:label>
                        <ce:section-title id="sectitle0125">5-Chloro-N-(3-methoxy-1,1-dioxo-2,3-dihydro-1H-1λ<ce:sup loc="post">6</ce:sup>-benzo[b]thiophen-6-yl)-2-hydroxybenzamide (<ce:bold>14</ce:bold>)</ce:section-title>
                        <ce:para id="p0150" view="all">To the solution of 5-chloro-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-hydroxybenzamide (335 mg, 1.0 mmol) in MeOH (8 mL) was added 10% NaOH (2 mL, 5.0 mmol) at 0 <ce:sup loc="pre">°</ce:sup>C. The mixture was stirred at r.t. for 15 min. The mixture was diluted with EtOAc (100 mL) and washed with 2 N HCl (20 mL) and brine (20 mL). The organic layer was separated and dried with anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solution was concentrated to afford the crude product, which was washed with CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (5 mL) to give the desired product (220 mg, 60%) as a pale yellow solid (mp 268–269 °C). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.52 (s, 1H), 10.73 (s, 1H), 8.24 (s, 1H), 7.95 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.88 (s, 1H), 7.70 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 7.49 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 7.03 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 5.17–5.18 (m, 1H), 3.96–3.99 (m, 1H), 3.65–3.67 (dd, 1H, <ce:italic>J</ce:italic> = 3.0, 13.8 Hz), 3.40 (s, 3H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.2, 156.3, 140.5, 139.8, 133.1, 132.7, 128.6, 128.3, 125.7, 122.8, 120.2, 119.0, 111.1, 74.5, 56.8, 56.0. HRMS (ESI) calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">15</ce:inf>ClNO<ce:inf loc="post">5</ce:inf>S 368.0354 (M + H)<ce:sup loc="post">+</ce:sup>, found 368.0357.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0130">Biology</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0135">
                           <ce:italic>In vitro</ce:italic> determination of effects of synthesized compounds on cancer cell proliferation</ce:section-title>
                        <ce:para id="p0155" view="all">Cancer cells (breast cancer cell lines MCF-7 and MDA-MB-231, pancreatic cancer cell lines AsPC-1 and Panc-1) were seeded in 96-well plates at a density of 2 × 10<ce:sup loc="post">3</ce:sup> cells/well and treated with DMSO, 0.01, 0.1, 1, 5, 10, and 100 μM of individual STAT3 inhibitors for 72 h. Proliferation was measured by treating cells with the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-((4-sulfophenyl)-2<ce:italic>H</ce:italic>-tetrazolium) (MTS) in a CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA). Absorbance of all wells was determined by measuring OD at 550 nm after 1 h incubation at 37 °C on a 96-well iMark™ Microplate Absorbance Reader (BioRad, Hercules, CA). Each individual compound was tested in quadruplicate wells for each concentration.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0140">Transient transfection and dual luciferase reporter assays</ce:section-title>
                        <ce:para id="p0160" view="all">MDA-MB-231 cells were pre-treated with stattic or <ce:bold>12</ce:bold> at 5 μM for 24 h. Then the cells were trypsinized and seeded in 24-well plate at a density of 5 × 10<ce:sup loc="post">4</ce:sup> cells/well in RPMI-1640 medium containing 10% FBS and 1% penicillin-streptomycin. Transient transfections were performed 4 h after plating, using the previously described method <ce:cross-refs refid="bib18 bib24" id="crosrefs0035">[18,24]</ce:cross-refs>. Total amount of DNA for transfections was 0.5 μg/well, including pSTAT3-Luc (95%, obtained from Panomics, Cat# LR0077) and internal control vector renilla (5%, from Promega, Madison, WI, USA). 5 h after transfection, the cells were treated with stattic or compound <ce:bold>12</ce:bold> for 24 h, and then reporter activity was evaluated using dual luciferase reporter assay kit (Promega, Madison, WI, USA) on an Omega™ Microplate Luminometer (BMG LABTECH Inc., NC, USA). Relative luciferase units were the ratio of the absolute activity of firefly luciferase to that of renilla luciferase. Experiments were conducted in triplicates and results are representatives of at least 3 independent experiments.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0145">Molecular docking studies</ce:section-title>
                        <ce:para id="p0165" view="all">Lead compound <ce:bold>1</ce:bold> and compound <ce:bold>12</ce:bold> were docked with the STAT3-SH2 domain (PDB code: <ce:inter-ref xlink:href="pdb:1BG1" id="intref0010" xlink:type="simple">1BG1</ce:inter-ref>) <ce:cross-ref refid="bib25" id="crosref0205">[25]</ce:cross-ref> and AutoDock Vina 1.1.2, using the method as previously described <ce:cross-refs refid="bib18 bib26 bib27" id="crosrefs0040">[18,26,27]</ce:cross-refs>. Water molecules within the crystal structure were removed and polar hydrogens were added using AutoDockTools. The protein was treated as rigid. Docking runs were carried out using the standard parameters of the program for interactive growing and subsequent scoring, except for the parameters for setting grid box dimensions and center. For all of the docking studies, a grid box size of 30 Å × 30 Å × 30 Å, centered at coordinates 100.452 (<ce:italic>x</ce:italic>), 75.972 (<ce:italic>y</ce:italic>), and 68.790 (<ce:italic>z</ce:italic>) of the PDB structure.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0150">Western blot analysis</ce:section-title>
                        <ce:para id="p0170" view="all">Protein levels were determined by Western blot using the previously reported methods <ce:cross-refs refid="bib18 bib24" id="crosrefs0045">[18,24]</ce:cross-refs>. Total cell lysates were prepared from MDA-MB-231 cells. Protein concentrations were measured using the BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). Equal amounts of total cellular protein extract (40 μg) were resuspended in denaturing sample loading buffer (0.5 M Tris–HCl, pH 6.8, 10% SDS, 0.1% bromophenol blue, and 20% glycerol), separated by electrophoresis on a 10% polyacrylamide SDS-PAGE gel and then electrophoretically transferred to a nitrocellulose membrane (Thermo Scientific, IL, USA) at 100 V for 1 h at 4 <ce:sup loc="pre">°</ce:sup>C. The membrane was then incubated in a blocking solution containing 5% non-fat milk and 1% Tween 20 in TBS for 1 h. The membrane was then incubated with antibodies specific for: phospho-STAT3-PY705 (1:3000, Epitomics, #2236-1), STAT3 (1:2000, Cell Signaling, #4904), Caspase-3-active (1:2000, Epitomics, #1476-1), Cyclin D1 (1:10,000, Epitomics, #2261-1) and β-actin (1:10,000, Sigma, clone AC-15). An anti-rabbit or anti-mouse secondary antibody (Amersham, Piscataway, NJ) was used at 1:4000 dilution. The Western blotted bands were visualized using ECL procedure according to the manufacturer's instructions (Amersham).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.5" view="all">
                        <ce:label>4.2.5</ce:label>
                        <ce:section-title id="sectitle0155">
                           <ce:italic>In vivo</ce:italic> antitumor activity assays</ce:section-title>
                        <ce:para id="p0175" view="all">All procedures including mice and <ce:italic>in vivo</ce:italic> experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of UT M.D. Anderson Cancer Center (MDACC). Thirty-one female nude mice were obtained from MDACC and were used for orthotopic tumor studies at 6 weeks of age. The mice were maintained in a barrier unit with 12 h light–dark switch. Freshly harvested MDA-MB-231 cells (2.5 × 10<ce:sup loc="post">6</ce:sup> cells per mouse, resuspended in 100 μL PBS) were injected into the 3rd mammary fat pad of the mice, and then randomly assigned into 5 groups (5–10 mice per group). For the intraperitoneal treatment experiment, the mice were treated daily with 10 mg/kg of compound <ce:bold>12</ce:bold> (<ce:bold>HJC0416)</ce:bold>, or vehicle when the tumor volume reached 150 mm<ce:sup loc="post">3</ce:sup>. Similarly, for the oral gavage experiment, the mice were given 100 mg/kg of <ce:bold>12</ce:bold>, or vehicle five days per week when the tumor volume reached 110 mm<ce:sup loc="post">3</ce:sup>. All drugs were dissolved in 50% DMSO with 50% polyethylene glycol for <ce:italic>in vivo</ce:italic> administration. Body weights and tumors volume were measured daily and tumor volume was calculated according to the formula <ce:italic>V</ce:italic> = 0.5 × <ce:italic>L</ce:italic> × <ce:italic>W</ce:italic>
                           <ce:sup loc="post">2</ce:sup>, where <ce:italic>L</ce:italic> = length (mm) and <ce:italic>W</ce:italic> = width (mm).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.6" view="all">
                        <ce:label>4.2.6</ce:label>
                        <ce:section-title id="sectitle0160">Statistical analysis</ce:section-title>
                        <ce:para id="p0180" view="all">Statistical significance was determined using student <ce:italic>t</ce:italic>-test in cell cycle analysis. * represents a <ce:italic>p</ce:italic> value less than 0.05.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:section-title id="sectitle0165">Conflict of interest</ce:section-title>
                  <ce:para id="p0185" view="all">The authors declare no competing financial interest.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0170">Acknowledgments</ce:section-title>
               <ce:para id="p0190" view="all">This work was supported by grants <ce:grant-number refid="gs1">P50 CA097007</ce:grant-number>, <ce:grant-number refid="gs1">P30 DA028821</ce:grant-number>, <ce:grant-number refid="gs1">R21 MH093844</ce:grant-number> (JZ) from the <ce:grant-sponsor id="gs1" sponsor-id="http://dx.doi.org/10.13039/100000002" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Institutes of Health</ce:grant-sponsor>, a grant from <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Duncan Family Institute Seed Funding Research Program</ce:grant-sponsor> and a startup fund from <ce:grant-sponsor id="gs3" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">MD Anderson Cancer Center (QS)</ce:grant-sponsor>, <ce:grant-sponsor id="gs4" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">R. A. Welch Foundation Chemistry and Biology</ce:grant-sponsor> Collaborative Grant from the <ce:grant-sponsor id="gs5" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Gulf Coast Consortia (GCC)</ce:grant-sponsor>, a training fellowship from the Keck Center for Interdisciplinary Bioscience Training of the GCC (NIGMS grant <ce:grant-number refid="gs5">T32 GM089657-03</ce:grant-number>), <ce:grant-sponsor id="gs6" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Sealy and Smith Foundation</ce:grant-sponsor> grant (to the Sealy Center for Structural Biology and Molecular Biophysics), <ce:grant-sponsor id="gs7" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">John Sealy Memorial Endowment Fund</ce:grant-sponsor>, and the <ce:grant-sponsor id="gs8" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Center for Addiction Research (CAR)</ce:grant-sponsor> at UTMB. We thank Drs. Lawrence C. Sowers, Jacob A. Theruvathu, and Tianzhi Wang for the NMR spectroscopy assistance, as well as Drs. Huiling Liu and Carol Nilsson for mass spectrometry assistance.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0175">Supplementary data</ce:section-title>
                  <ce:para id="p0195" view="all">The following is the supplementary data related to this article:<ce:display>
                        <ce:e-component id="ec1">
                           <ce:link locator="mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0180">Supplementary data</ce:section-title>
                  <ce:para id="p0200" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2014.05.049" id="intref0015" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2014.05.049</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0185">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs and gene regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1630</sb:first-page>
                              <sb:last-page>1635</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2474</sb:first-page>
                              <sb:last-page>2488</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STATs in transcriptional control and their impact on cellular function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2468</sb:first-page>
                              <sb:last-page>2473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT proteins: novel molecular targets for cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6613</sb:first-page>
                              <sb:last-page>6626</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat proteins and oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1139</sb:first-page>
                              <sb:last-page>1142</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in cancer inflammation and immunity: a leading role for STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting STAT3 in cancer: how successful are we?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45</sb:first-page>
                              <sb:last-page>56</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Avadisian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>115</sb:first-page>
                              <sb:last-page>127</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Mora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>945</sb:first-page>
                              <sb:last-page>954</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Wrzeszczynska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Devgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Pestell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Albanese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 as an oncogene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>295</sb:first-page>
                              <sb:last-page>303</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer–new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Validating Stat3 in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>595</sb:first-page>
                              <sb:last-page>596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Grande</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of Stat3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Cancer Drug Targ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>91</sb:first-page>
                              <sb:last-page>107</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Al Zaid Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 as a target for inducing apoptosis in solid and hematological tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>254</sb:first-page>
                              <sb:last-page>267</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 inhibitors: a patent review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Hann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Keseru</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Finding the sweet spot: the role of nature and nurture in medicinal chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>355</sb:first-page>
                              <sb:last-page>365</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>507</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of -Alkylamino tethered niclosamide derivatives as potent and orally bioavailable anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>180</sb:first-page>
                              <sb:last-page>185</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Innocenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Villar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Martinez-Merino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Gil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Scozzafava</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Vullo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Supuran</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4872</sb:first-page>
                              <sb:last-page>4876</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.T.</ce:given-name>
                                 <ce:surname>McKinley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Hight</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Uddin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Harp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Nickels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Buck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Manning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3429</sb:first-page>
                              <sb:last-page>3433</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small-molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Trott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>455</sb:first-page>
                              <sb:last-page>461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.P.</ce:given-name>
                                 <ce:surname>Uray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.I.</ce:given-name>
                                 <ce:surname>Krisko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Strecker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.T.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>366</sb:first-page>
                              <sb:last-page>377</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Groner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three-dimensional structure of the Stat3beta homodimer bound to DNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>394</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>145</sb:first-page>
                              <sb:last-page>151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tsalkova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.C.</ce:given-name>
                                 <ce:surname>Mei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4038</sb:first-page>
                              <sb:last-page>4043</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Copits</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.T.</ce:given-name>
                                 <ce:surname>Swanson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>226</sb:first-page>
                              <sb:last-page>230</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>